Abstract: Primary adrenal lymphoma (PAL) is an exceedingly rare disease. Because of its rareness, uncertain etiology, variable duration of survival, unremarkable clinical presentations and unsatisfied therapeutic strategies, its treatment has always been unsatisfactory. Here we report a 50-year-old male patient with primary bilateral adrenal diffuse large B-cell lymphoma. He was treated with surgery followed by combined chemotherapy using R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). He achieved complete remission after 3 cycles of chemotherapy. At present, he is considered free of tumor at 3 years after chemotherapy. Our case report demonstrates that patients with primary bilateral adrenal diffuse large B-cell lymphoma may achieve a good outcome using R-CHOP chemotherapy. To the best of our knowledge, our patient who achieved complete remission after R-CHOP chemotherapy has had the longest survival as published in the literature.
Introduction
With no more than 90 cases reported in the English literature [1] , primary bilateral adrenal lymphoma is especially rare. It mainly occurs around the age of 65 (range 37-87 years) [2] , with a male-to-female ratio of about 2~7 : 1. According to recent studies, about 90% of primary adrenal lymphoma (PAL) is of the diffuse B-cell type; about 70%-80% of cases have bilateral adrenal involvement, and adrenal insufficiency is one of the complications [3] . As most cases of PAL are relatively malignant with poor prognosis, therapeutic modalities, which include surgery, combination chemotherapy and radiation, are used for the treatment. Even though an optimum treatment of PAL has not been established, our case has demonstrated that the patient's prognosis can be improved by adding rituximab (a monoclonal antibody) to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone).
Case report
A 50-year-old man was admitted to our department with the complaint of abdominal pain. Abdominal computed tomography (CT) was performed and magnetic resonance imaging (MRI) revealed inhomogeneous tumors involving the bilateral adrenal glands, with the right gland 
Discussion
Non-Hodgkin's lymphoma (NHL) comprises 90% of lymphoma. The most common subtype of NHL is diffuse large B-cell lymphoma, which is highly aggressive and has a poor prognosis. The most common manifestation of malignant lymphoma is involvement of the amygdala, stomach, and pharynx in addition to the lymph nodes. Involvement of the adrenal gland in malignant lymphoma is reported to be 25% at autopsy [4] . Common symptoms of PAL include fever, weight loss, and abdominal/lumbar pain, which also occurred in our patient. Imaging findings and clinical symptoms are non-specific, making diagnosis of PAL difficult.
Histologically, the most common subtype (about 90%) of PAL is diffuse large B-cell lymphoma. Other less commonly found histological types are the mixed large and small cell, small noncleaved cell, and undifferentiated types. These neoplastic cells express antigens specific to B lymphocytes, such as CD20, CD74, CDw75 and CD79a; however, they do not express antigens specific to T lymphocytes, such as CD3, CD5, CD43 and CD45RO. Immunoassays show that the majority of PALs are of B cell origin; and only 10 cases of T cell origin have been reported to date [5, 6] .
Imaging studies show that lesions are characteristically bilateral and variably dense, often with areas of necrosis and/or hemorrhage, but in some cases, a secondary tumor should be considered when the lesions appear to be homogenously dense. With the diagnosis being mainly differentiated from metastatic carcinoma, bilateral lesions >6 cm are suggestive of malignancy [7, 8] . Definite histopathological diagnosis requires core biopsy guided by ultrasound or CT or surgical biopsy through laparoscopy or laparotomy.
Patients with PAL may have more than 3 adverse risk factors including advanced age, large tumor size, increased LDH level, bilateral adrenal involvement (regarded as stage IV disease), and adrenal insufficiency at the time of presentation, indicating extensive adrenal destruction; the prognosis is deemed very poor [9] . Given its poor prognosis, unremarkable clinical presentations, and non-optimal diagnosis, therapeutic modalities including surgery, combination chemotherapy, and radiation are administered. However, the roles of radiation therapy and surgical excision of the adrenal glands in the context of bilateral involvement are still not clear. While the standard chemotherapy for patients with NHL is CHOP, there are also new chemotherapy protocols for treatment of NHL. In a study by M Mori et al., THP (pirarubicin)-COP (cyclophosphamide, vincristine, and prednisolone) was compared to a two-thirds dosage of the full CHOP regimen with regard to both adverse events and efficacy in elderly patients with non-Hodgkin's lymphoma. In a third group, etoposide (E) was added to the THP-COP regimen (THP-COPE) to achieve high dose intensity. In aggressive lymphoma, there were no differences in complete response (CR) rates (45.3% in THP-COP, 44.9% in CHOP, 48.0% in THP-COPE), overall survival, and progression-free survival among these groups [10] .
Rituximab, a chimeric anti-CD20 monoclonal antibody, is mainly used for recurrent low-grade or follicular non-Hodgkin's lymphoma; it can make the lymphoma cells more sensitive to chemotherapy. In the review by GM Keating, in patients with previously untreated advanced follicular lymphoma, the addition of rituximab to CHOP, CVP (cyclophosphamide, vincristine and prednisone) was generally associated with better outcomes than chemotherapy alone in randomized, multicentre trials [11] . Monotherapy with rituximab also demonstrated efficacy in patients with relapsed or refractory low-grade or follicular lymphoma. It also has therapeutic activity in diffuse large B-cell lymphoma. Recently, the combination of rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy has been shown to improve clinical outcome when compared with CHOP alone in patients with diffuse large B-cell lymphomas [12] . In four randomized, open-label, multicentre trials in younger or elderly patients with previously untreated diffuse large B-cell lymphoma, event-free survival, failure-free survival, progression-free survival, and overall survival were generally improved to a significant extent by the addition of rituximab to CHOP or CHOP-like chemotherapy [11] .The emergence of rituximab for clinical treatment has substantially improved the event-free survival and overall survival in both elderly and younger patients with diffuse large B-cell lymphoma [12, 13] . N Colovic et al. have reported good efficacy of rituximab in combination with CHOP in a patient with histologically aggressive primary cutaneous B-cell non-Hodgkin's lymphoma, The patient achieved an excellent clinical and histological response without side effects [14] .
Chemotherapy for PAL treatment has been similar to treatment of other types of NHL; there is only scant literature reporting the systemic treatment of PAL with rituximab alone or in combination with other chemotherapeutic agents. A 62-year-old Japanese man with primary bilateral diffuse large B-cell lymphoma has been disease free for 2 years after a left adrenalectomy, R-CHOP, radiotherapy, and high-dose chemotherapy with autologous peripheral blood stem cell transplantation [15] . On the other hand, a 52-year-old Korean man showed complete remission on follow-up with only 6 cycles of R-CHOP every 3 weeks, no surgery, and no radiation or high-dose therapy [16] . To the best of our knowledge, our patient who achieved complete remission after R-CHOP chemotherapy had the longest survival in the literature to date. Rituximab remains a valuable therapy in patients with diffuse large B-cell lymphoma.
In summary, due to the rarity of PAL, its uncertain etiology, variable duration of survival, unremarkable clinical presentation, and unsatisfactory therapeutic strategies, its treatment has always produced less than optimal results. However, our case report demonstrates that patients with primary bilateral adrenal diffuse large B-cell lymphoma may achieve a good outcome through R-CHOP chemotherapy.
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